BioCentury
ARTICLE | Clinical News

Prothena sees potential path forward for amyloidosis candidate

April 26, 2019 8:00 PM UTC

Prothena said it will explore business development opportunities that could lead to further clinical investigation of amyloid light-chain (AL) amyloidosis candidate birtamimab (NEOD001) after post hoc analyses of the Phase III VITAL trial showed a potential survival benefit in a subgroup of patients at highest risk for early mortality.

Prothena Corp. plc (NASDAQ:PRTA) said a post hoc analysis of all-cause mortality by Mayo Stage showed an HR of 0.54 (95% CI: 0.27, 1.08, p=0.079) in favor of birtamimab vs. placebo among 77 AL amyloidosis patients categorized as Mayo Stage IV...

BCIQ Company Profiles

Prothena Corp. plc

BCIQ Target Profiles

Amyloid